home / stock / imrx / imrx news

IMRX News and Press, Immuneering Corporation From 03/06/24

Stock Information
Company Name: Immuneering Corporation
Stock Symbol: IMRX
Market: NASDAQ
Website: immuneering.com
Menu
IMRX IMRX Quote IMRX Short IMRX News IMRX Articles IMRX Message Board
Get IMRX Alerts

News, Short Squeeze, Breakout and More Instantly...
IMRX - Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market

2024-03-06 09:10:00 ET March 6, 2024 Investorideas.com , a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Biotech Inc. ( NASDAQ: ONCY ) (TSX: ONC ), a clinical-stage i...
IMRX - Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth

2024-03-06 08:40:19 ET Vancouver, Kelowna and Delta, British Columbia – March 6, 2024 – Investorideas.com , a global investor news source covering biotech and pharma stocks issues a sector snapshot on developments for pancreatic cancer treatments, featuring Oncolytics Bi...

IMRX - Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on ...

IMRX - Immuneering to Participate in the Cowen 44th Annual Health Care Conference

CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Co...
IMRX - Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a portion of Phase 1/2a trial of IMM-1-104 expected in March 2024; initial data from multiple arms expected in 2024 - - FDA Fast Track...

IMRX - Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

– Fast Track designation has the potential to accelerate lead asset IMM-1-104’s path to U.S. FDA submission for pancreatic ductal adenocarcinoma – – Company expects multiple readouts from its Phase 1/2a clinical trial in 2024 - CAMBRIDGE, Mass., Feb. 20...

IMRX - Immuneering Announces Participation in February Investor Conferences

CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferen...
IMRX - (IMRX) Trading Report

2024-01-19 19:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

IMRX - When (IMRX) Moves Investors should Listen

2024-01-09 03:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

IMRX - Learn to Evaluate Immuneering Corporation ($IMRX) using the Charts

2023-12-14 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Previous 10 Next 10